Skip to content

Evaluation of the Efficacy of Intralesional Injection of Combined Digoxin and Furosemide Versus 5 - Fluorouracil in Treatment of Plantar Warts

Evaluation of the Efficacy of Intralesional Injection of Combined Digoxin and Furosemide Versus 5 - Fluorouracil in Treatment of Plantar Warts

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05520658
Enrollment
60
Registered
2022-08-30
Start date
2022-07-01
Completion date
2022-09-30
Last updated
2022-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plantar Wart

Brief summary

Warts are common skin infections caused by human papillomavirus (HPV), which can cause a variety of skin presentations according to its type, site and the immune status .Nongenital warts may be presented as common, plane, plantar, filiform, or mucosal warts .Most people are affected by cutaneous warts, either plantar warts or common warts .prevalence of skin warts is between 3% and 13% and plantar warts are about 30% of skin warts in western world .Majority of cases occur in adolescent and young adults

Interventions

DRUGcombined digoxin and furosemide

one session every 2 weeks for maximum 6 sessions

5 fluorouracil mixed with1ml of 2% lignocaine and epinephrine one session every 2 weeks for maximum 6 sessions .

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age:\>18 years . * Sex: both males and females will be included. * Confirmed diagnosis by clinical and dermoscopic examination of plantar warts will be made

Exclusion criteria

* Patients with history or evidenced hypersensitivity to any component used in this study. * Pregnancy & lactating. * Patients who receive immune suppressive therapy. * Patients who receive any wart treatment during the last 2 months before enrollment in the study. * Patients with systemic illness especially cardiac patients. * Patients who refused participation in the study

Design outcomes

Primary

MeasureTime frameDescription
the change in size of plantar wart3 monthmeasurement the change in size of plantar wart
the change in number of plantar warts3 monthmeasurement the change in number of plantar warts

Countries

Egypt

Contacts

Primary Contactsamah R Ahmed, resident
samah_ragab_post@med.sohag.edu.eg01128636414
Backup ContactEssam A Nada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026